

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANTIBE HOLDINGS INC.	07/19/2011
RECEIVING PARTY DATA	
Name:	GICARE PHARMA INC.
Street Address:	2202 d'Oxford Avenue
City:	Montreal
State/Country:	CANADA
Postal Code:	H4A 2X8
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7666907
CORRESPONDENCE DATA	
Fax Number:	(514)845-7874
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	514 987-6242
Email:	desaulniers@robic.com
Correspondent Name:	ROBIC
Address Line 1:	1001 Square-Victoria, Bloc E - 8th Floor
Address Line 4:	Montreal, CANADA H2Z 2B7
ATTORNEY DOCKET NUMBER:	015117-0009
NAME OF SUBMITTER:	Melanie Desaulniers
Total Attachments: 5 source=015117-0009assignment#page1.tif source=015117-0009assignment#page2.tif source=015117-0009assignment#page3.tif source=015117-0009assignment#page4.tif source=015117-0009assignment#page5.tif	

OP \$40.00 7666907

PATENT

501629526

REEL: 026766 FRAME: 0143

Express Mail Label No.:

Date of Deposit:

Attorney Docket No.

EXECUTION COPY

ASSIGNMENT

The undersigned, **ANTIBE HOLDINGS INC.**, an Alberta Corporation, with offices at 1063 King Street West, Suite 210, Hamilton, Ontario, L8S 4S3 (the "**ASSIGNOR**"), for good and valuable consideration, the receipt of which is hereby acknowledged, confirms that the **ASSIGNOR** has sold and assigned, and does hereby assign, sell and transfer to **GICARE Pharma Inc.**, with offices at 2202 d'Oxford Avenue, Montreal, Quebec, H4A 2X8, and to its successors, assigns and legal representatives, collectively hereinafter referred to as the **ASSIGNEE**: (1) the **ASSIGNOR**'s entire right, title and interest for the United States and in all countries throughout the world, in and to any and all inventions, which are disclosed in the patents and patent applications listed in Annex A including the application for United States Letters Patent entitled:

SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE

filed with the U.S. Patent and Trademark Office on June 6, 2007 and assigned Application No.12/303,082, including any other patent applications, which claim priority to Application No.60/084,067, and including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the **ASSIGNEE**, its designee or its designee's election, on the aforesaid inventions in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent issued or which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications; and (5) the right to sue under said patents and to recover and retain any damages or profits as a result thereof.

The **ASSIGNOR** hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the **ASSIGNEE** of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by the **ASSIGNOR** had this assignment, sale and transfer not been made.

The **ASSIGNOR** agrees at any time to execute and to deliver upon request of the **ASSIGNEE** such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the **ASSIGNEE** under this Assignment, including but not limited to the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

The **ASSIGNOR** hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

First Inventor :
Application No. :
Filed :
Page 2 of 5

The ASSIGNOR further covenants that ASSIGNEE will, upon its reasonable request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. Any expense incurred by the ASSIGNOR in complying with the foregoing, other than nominal out-of-pocket expenses, shall be reimbursed by the ASSIGNEE.

[Remainder of this page intentionally left blank. The next page is the signature page.]

First Inventor :
Application No. :
Filed :
Page 3 of 5


ANTIBE HOLDINGS INC.

Per:

Date: July 19, 2011


Name: Dan Legault
Title: President and Chief Executive Officer

IN WITNESS WHEREOF, I, Basia Ujejska, hereby declare
(Printed Name of Witness)
that I was personally present and did see the above named person duly sign and execute the assignment.


(Signature of Witness)

Date: July 19, 2011

IN WITNESS WHEREOF, I, _____, hereby declare
(Printed Name of Witness)
that I was personally present and did see the above named person duly sign and execute the assignment.

(Signature of Witness)

Date: _____

[Signature page to the Patent Assignment]

Annex A
TO THE PATENT ASSIGNMENT

SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE

	Country	Application Number	Filing date	Publication or Patent Number	Publication date or Issue Date
1.	USA	USSN provisional application 60/804,067	June 6th 2006		
2.	WIPO	PCT/CA2007/001008	June 6th 2007	WO2007/140611	December 13th 2007
3.	Australia		June 6th 2007	AU2007257174	December 13th 2007
4.	Canada		June 6th 2007	CA2653869	December 13th 2007
5.	China		June 6th 2007	CN101489986	July 22 2009
6.	Europe		June 6th 2007	EP2024323	February 18 2009
7.	India		June 6th 2007	IN2008DN10097	
8.	Japan		June 6th 2007	JP2009539777	November 19 2009
9.	Rebublic of Korea		June 6th 2007	1020087029794 KR20090021346	March 03 2009
10.	Russian Federation		June 6th 2007	RU2008152751	July 20, 2010

First Inventor :
Application No. :
Filed :
Page 5 of 5

	Country	Application Number	Filing date	Publication or Patent Number	Publication date or Issue Date
11.	USA	USSN 11/759,154 CIP of PCT/CA2006/000484 and Claiming priority of US 60/804,067	June 6th 2007	US 7,666,907	February 23, 2010
12.	USA	USSN 12/303,082	June 6th 2007	US 2011/0144188	June 16, 2011